Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and for working capital, capital expenditures and general corporate purposes. All of the securities are to be sold by the Company. The offering is expected to close on or about August 15, 2025, subject to satisfaction of customary closing conditions.

WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP (“RTW”), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions.

While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.03 per share a year ago.

WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit , which will be held June 27-29 in Chicago, Ill. The data from these posters was originally presented at the 2025 AAAAI Annual Meeting. If approved by the U.S. Food and Drug Administration (FDA), Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.

Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and high patient/provider preference—position it to capture significant share of a $2B U.S. market. My risk-adjusted DCF analysis values AQST at $5/share ( at just 10% market share), indicating the stock is undervalued at current levels.

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghuram Selvaraju - HC Wainwright Dennis Resnick - Raymond James Nelson Cox - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call.

AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.

Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential.